Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Giampaolo Bianchini et al.|Journal of Clinical Oncology|2024Cited by 75
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Stacy L. Moulder et al.|Cancer Research|2025Cited by 2
Data from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Yuan Qi et al.|Unknown|2025Cited by 0
Supplementary Figure S11 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Yuan Qi et al.|Unknown|2025Cited by 0
Supplementary Figure S12 from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Yuan Qi et al.|Unknown|2025Cited by 0